Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Nat Med. 2015 Aug 31;21(10):1209–1215. doi: 10.1038/nm.3931

Figure 1. Anti-tumor effects of anti-CD47 depend on T cells.

Figure 1

(a) Balb/c mice (n=5/group) transplanted s.c. with 5×106 A20 cells were treated intraperitoneally with 400µg of anti-mCD47or isotype control rat Ig on days 7, 9, 11 and 13. (b) BALB/c mice (n=5/group) were injected s.c. with 5×106 A20 cells and treated intratumorally with 50µg of anti-CD47 or isotype control rat Ig on days 11 and 16. (c) C57BL/6 mice (n=5/group) were injected s.c. with 106 MC38 cells and treated intratumorally with 50µg of anti-CD47 or isotype control rat Ig on days 10 and 14. One of three representative experiments is shown. (d) A20 tumor-bearing Balb/c mice (n=5/group) were injected s.c. with 5×106 A20 cells and treated twice with 50µg of Sirpα-hIg or human intratumorally on days 15 and 20 (e) Balb/c nude mice (n=4/group) were injected s.c. with 2×106 A20 cells and intratumorally injected with 50µg of anti-CD47 or isotype control rat Ig on days 7 and 11. (f) 2×106 A20 were transplanted subcutaneously on Balb/c nude mice. When tumors were established (> 50 mm3), treatment began with daily intratumoral injections of 50 µg anti-CD47or 50 µg rat Ig for one week since day 10. Tumor growth is reported as the mean tumor size ±s.e.m. over time. One representative experiment out of three (b–c) or two (a, d-f) yielding similar results is depicted. ns (nonsignificant), *p < 0.05, **P < 0.01 (unpaired Student's t test) compared to tumors treated with RatIg.